VExUS Score and AKI in Critically Ill Adult patients-a Prospective Observational Study.

March 20, 2025 updated by: Bipin Karki, Tribhuvan University Teaching Hospital, Institute Of Medicine.

Correlation of Point of Care Venous Excess Ultrasonography (VExUS) Score and Acute Kidney Injury (AKI) in Critically Ill Adult Patients- a Prospective Observational Study.

Introduction Renal perfusion is dependent on the renal perfusion pressure across the renal capillaries. Venous congestion due to excess fluid therapy can drastically reduce the renal perfusion pressure in spite of a normal mean arterial pressure. Increasing cumulative fluid balance during the ICU stay has been found to be associated with negative outcomes including acute kidney injury (AKI) and hospital mortality. Venous excess ultrasound (VExUS) to assess the Doppler studies of renal, hepatic and portal veins along with the inferior venacava has been shown to reliably predict the incidence of AKI in certain ICU patient population more specifically in cardiorenal syndrome. The aim of this study was to correlate the incidence of AKI and VExUS scores in a mixed ICU population and hence determine the contribution of venous congestion on the causation of AKI in a general ICU.

Methods:

The patients included who have AKI at admission or developed AKI during their ICU stay were included. The definition of AKI used for this study was as defined by Kidney Disease: Improving Global Outcomes (KDIGO). Point of care VExUS scans were done on each patient at inclusion (day 0), then each day for a total of 4 days (day 1, 2 and 3), till initiation of renal replacement therapy, death or discharge form the ICU. Correlation between VExUS grades and creatinine clearances was explored as the primary objective.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

52

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Nepal
    • Bagmati
      • Maharajganj, Bagmati, Nepal, 44600
        • Tribhuvan University Teaching Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients who had AKI at the time of admission or who developed AKI during their ICU stay were screened for inclusion.

Description

Inclusion Criteria:

  • Age ≥18 years
  • Admitted to the adult ICUs of TUTH (ICU A and ICU B)
  • Admitting diagnosis of AKI or who developed AKI during their ICU stay

Exclusion Criteria:

  • Pregnancy
  • Diagnosed case of chronic kidney disease
  • Diagnosed case of cirrhosis/ portal hypertension
  • Arrhythmias which would interfere with the acquisition and interpretation of the Doppler waveforms
  • Inferior venacava thrombus
  • Poor window for assessment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients with AKI
Patients who are admitted with the diagnosis of AKI or develop AKI during their ICU stay

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To determine correlation between the VExUS score with creatinine clearance.
Time Frame: At the end of Day 3 or initiation of renal replacement therapy or resolution of AKI, death or discharge from the ICU. whichever came first.
At the end of Day 3 or initiation of renal replacement therapy or resolution of AKI, death or discharge from the ICU. whichever came first.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tribhuvan University Teaching Hospital, Institute Of Medicine.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 15, 2023

Primary Completion (Actual)

January 7, 2024

Study Completion (Actual)

January 11, 2024

Study Registration Dates

First Submitted

March 15, 2025

First Submitted That Met QC Criteria

March 20, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 20, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 438(6-11)E2- 079/080

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Kidney Injury

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe